Development of allosteric activators for immunotherapy

One major unmet medical need in the development of immunotherapies is to expand the cohort of patients who experience durable immune responses.  Here, we propose to develop nanobody- or antibody-based biologics that function as allosteric activators of a receptor for use in immunotherapy applications. Use of a target-restricted biologic will eliminate the lack of specificity associated with engineered activating ligands, which stimulate all receptors in the family.